Fotemustine: Difference between revisions
m Protected "Fotemustine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
No edit summary |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
<div style="float: right;"> | |||
[[File:Fotemustine.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div> | |||
__NOTOC__ | |||
| | |||
| | |||
| | |||
| | |||
{{SI}} | {{SI}} | ||
{{ | {{CMG}} | ||
==Overview== | |||
'''Fotemustine''' is a [[nitrosourea]] [[alkylating antineoplastic agent|alkylating agent]] approved for use in the treatment of [[metastasis]]ing [[melanoma]]. A study has shown that fotemustine produces improved response rates and but does not increase survival (over [[dacarbazine]] in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively). | |||
== | ==References== | ||
{{reflist|2}} | |||
{{Chemotherapeutic agents}} | {{Chemotherapeutic agents}} | ||
[[Category:Nitrosoureas]] | |||
[[Category:Ureas]] | |||
[[Category:Organochlorides]] | |||
[[Category:Drug]] | |||
[[Category: | |||
Latest revision as of 15:43, 7 April 2015
|
WikiDoc Resources for Fotemustine |
|
Articles |
|---|
|
Most recent articles on Fotemustine Most cited articles on Fotemustine |
|
Media |
|
Powerpoint slides on Fotemustine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Fotemustine at Clinical Trials.gov Clinical Trials on Fotemustine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Fotemustine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Fotemustine Discussion groups on Fotemustine Patient Handouts on Fotemustine Directions to Hospitals Treating Fotemustine Risk calculators and risk factors for Fotemustine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Fotemustine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Fotemustine is a nitrosourea alkylating agent approved for use in the treatment of metastasising melanoma. A study has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).